470 related articles for article (PubMed ID: 21819517)
1. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
2. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
3. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
5. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
6. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
7. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
8. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
9. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
[TBL] [Abstract][Full Text] [Related]
12. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
[TBL] [Abstract][Full Text] [Related]
13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
14. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
[TBL] [Abstract][Full Text] [Related]
15. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
Fogelfeld L; Dharmalingam M; Robling K; Jones C; Swanson D; Jacober S
Diabet Med; 2010 Feb; 27(2):181-8. PubMed ID: 20546262
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
18. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
[TBL] [Abstract][Full Text] [Related]
20. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]